Alphabet Inc. Makes New Investment in Spero Therapeutics, Inc. $SPRO

Key Points

• Alphabet acquired 889,979 shares of Spero Therapeutics in the second quarter, worth approximately $1.97 million and representing about 1.54% of SPRO’s outstanding shares.
• Spero shares opened at $1.19, down 3.3%, near the bottom of their 12-month range of $1.08 to $3.08. The company reported a quarterly loss of $0.16 per share, slightly beating analyst estimates.
• Analysts maintain a consensus “Hold” rating, while institutional investors and hedge funds collectively own 25.6% of the company.

Alphabet Inc. bought a new stake in Spero Therapeutics, Inc. (NASDAQ:SPRO - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 889,979 shares of the company's stock, valued at approximately $1,967,000. Spero Therapeutics comprises approximately 0.0% of Alphabet Inc.'s investment portfolio, making the stock its 26th biggest position. Alphabet Inc. owned about 1.54% of Spero Therapeutics as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently bought and sold shares of the business. GSK plc acquired a new stake in shares of Spero Therapeutics during the fourth quarter worth $21,414,000. Vanguard Group Inc. increased its stake in Spero Therapeutics by 2.0% in the third quarter. Vanguard Group Inc. now owns 1,989,855 shares of the company's stock valued at $3,741,000 after purchasing an additional 39,474 shares during the last quarter. GSA Capital Partners LLP acquired a new position in Spero Therapeutics in the second quarter valued at $632,000. State Street Corp lifted its position in Spero Therapeutics by 10.1% during the fourth quarter. State Street Corp now owns 210,151 shares of the company's stock worth $490,000 after buying an additional 19,200 shares during the period. Finally, Intrepid Family Office LLC lifted its position in Spero Therapeutics by 50.0% during the fourth quarter. Intrepid Family Office LLC now owns 165,000 shares of the company's stock worth $384,000 after buying an additional 55,000 shares during the period. 25.60% of the stock is currently owned by institutional investors and hedge funds.

Spero Therapeutics Trading Down 3.3%

Shares of SPRO opened at $1.19 on Tuesday. The firm has a market capitalization of $68.90 million, a P/E ratio of 10.82 and a beta of 1.55. The stock's fifty day simple moving average is $1.80 and its 200 day simple moving average is $2.27. Spero Therapeutics, Inc. has a twelve month low of $1.08 and a twelve month high of $3.08.

Spero Therapeutics (NASDAQ:SPRO - Get Free Report) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.17) by $0.01. Spero Therapeutics had a return on equity of 16.17% and a net margin of 24.90%.

Wall Street Analysts Forecast Growth

Several research firms have commented on SPRO. Weiss Ratings upgraded Spero Therapeutics from a "sell (d-)" rating to a "hold (c-)" rating in a report on Wednesday, August 12th. Wall Street Zen lowered shares of Spero Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Saturday, May 16th. Two investment analysts have rated the stock with a Hold rating, According to MarketBeat, the stock has a consensus rating of "Hold".

About Spero Therapeutics

Spero Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel therapies to address multidrug‐resistant bacterial infections. Headquartered in Boston, Massachusetts, the company aims to advance a pipeline of oral and intravenous antibiotic candidates designed to treat serious infectious diseases that pose significant public health challenges.

The company's lead candidate, tebipenem HBr, is an oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections caused by resistant Gram‐negative pathogens.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source